Waterloo targets translational health technologies with a tenure-track hire backed by federal funding
The University of Waterloo’s Faculty of Engineering is recruiting for a Canada Impact+ Emerging Leader in translational health technologies, a tenure-track assistant professorship aimed at an internationally renowned scholar with a record of research excellence and teaching. The appointment carries an anticipated start date of July 1, 2027, and a salary range of $120,000 to $160,000, with the possibility of negotiation beyond that range for exceptionally qualified candidates.
The position sits at the intersection of engineering and health innovation. It is designed for an early career researcher whose work can move beyond basic discovery and into tangible clinical or commercial use. The university is looking for someone whose research program can generate measurable benefits for Canadians through knowledge mobilization, translation, or commercialization, while also building an independent academic profile inside a major engineering faculty.
The structure of the role is unusually expansive for a junior faculty appointment.
Federal support aims to accelerate health and biotechnology research
The Canada Impact+ Emerging Leaders Program is a one-time federal initiative intended to help Canadian institutions recruit exceptional early career researchers with demonstrated excellence in both research and teaching. For the selected candidate, the award includes $100,000 per year in research support for six years, with the possibility of renewal for an additional six years. Eligibility is restricted to nominees who are within five years of the start date of their first full-time, independent research-related appointment, after eligible career delays or interruptions are accounted for, and who are working and residing outside Canada as of July 5, 2026.
Those requirements make the search highly specific. This is not a broad faculty posting; it is a targeted effort to bring in a researcher who is already operating at an advanced level but still fits the federal definition of an emerging leader. The program is aligned with the strategic priority area of Health, including Biotechnology, which places translational science at the center of the appointment rather than as a peripheral interest.
In practical terms, the funding package reduces one of the central barriers to early independent research: the need to secure enough support to launch a serious program before it can mature. A six-year research envelope can be decisive for technologies that require iterative development, validation in model systems, and eventual movement toward clinical or industrial application.
Mechanobiology, biomaterials, and organ-on-chip work sit at the center of the search
Waterloo is seeking a candidate with a PhD in Biomedical, Chemical, Mechanical, Electrical Engineering, or an equivalent discipline. The preferred research profile spans translational mechanobiology and human health, including in vitro, in vivo, and ex vivo model systems. The scope is broad, but the emphasis is clear: the university wants work that can connect mechanistic insight to a translational endpoint.
Specific areas named in the posting include organ-system mechanobiology in cardiovascular, musculoskeletal, pulmonary, renal, neural, or endocrine systems; mechano-oncology and fibrosis; microphysiological systems and organs-on-chips; functional tissue engineering and advanced biomaterials; advanced biofabrication and 3D bioprinting; mechanotransduction signaling; cell and gene therapies and delivery; and quantitative biomechanical imaging and characterization.
That list reflects where biomedical engineering has been moving clinically. Mechanical forces are not an abstract add-on to biology; they shape cell behavior, tissue remodeling, fibrosis, and tumor progression. A researcher who studies how cells sense and respond to force can influence how engineered tissues are built, how disease models are designed, and how future therapies are delivered or tested. The appointment is therefore aimed at a scientist who can work across systems and scales, from molecular signaling to organ-level function.
The faculty also expects the new hire to collaborate with the Eddie Goldenberg Research Chair in Supramolecular Biomaterials and with other Waterloo faculty members. That expectation signals a collaborative environment in which materials science, engineering, and health technologies intersect. Access to the university’s health and biotechnology facilities and infrastructure is part of the package, giving the incoming professor the resources needed to build a platform in an area where translation often depends on shared technical capability.
Teaching, licensing, and research leadership are built into the appointment
The successful applicant will be expected to lead an independent research program, teach at the undergraduate and graduate levels, supervise graduate students, and contribute to administrative service within the university and the international research community. Excellent communication skills and a commitment to both teaching and research are listed as core qualifications, not optional strengths.
A notable requirement is the expectation that the successful applicant will apply for a Canadian engineering license within the first year of joining the university. That detail matters because it ties the role to the professional practice culture of engineering, not only to scholarship. It also signals that the appointment is meant to sit within a framework where academic research, professional standards, and translational application remain closely linked.
Waterloo also frames its review process in a way that acknowledges non-linear research careers. Illness, disability, family and community responsibilities, caregiving leave, chronic illness, disability, maternity or parental leave, and COVID-19-related disruptions are all named as factors that can affect the pace and nature of research contributions. Those circumstances will be considered in assessment, and candidates are invited to provide context so that achievements can be evaluated fairly.
Waterloo is using the appointment to reinforce its health-tech strategy
The university is positioning the hire inside a broader institutional push toward health-focused innovation. Waterloo describes its strategic vision, Waterloo at 100, as including major investment in Health Futures, with emphasis on the intersection of health, society, technology, and entrepreneurship. A new regional hospital planned on campus, partnerships with the healthcare ecosystem, and a newly constructed Innovation Arena are all presented as part of the infrastructure supporting capital-intensive health technology research.
The institution also points to its scale and research capacity. Waterloo has 42,000 students, 220,000 alumni in 151 countries, more than 7,000 employer partners worldwide, 74 Canada Research Chairs, and more than $96 million in annual research funding. It says the engineering faculty ranks among the top Canadian and global programs, and it emphasizes a 100% creator-owned intellectual property policy that gives researchers ownership of their IP and freedom to commercialize as they see fit.
For a translational health technologies appointment, that combination is strategically important. Researchers in this field often need both laboratory resources and a pathway toward application. Ownership of intellectual property, institutional support for commercialization, and proximity to a health system can all affect whether a prototype, device, or biomaterial remains a publication or becomes a deployable platform.
The posting closes with a set of equity, inclusion, and accessibility commitments, including the university’s Indigenous verification process, support for applicants from historically disadvantaged and marginalized groups, and accommodations for disabilities or workplace needs. The competition gives priority to Canadians and permanent residents, but the candidate pool is clearly intended to be international in scope. The final deadline for applications is December 15, 2026, with three reference letters requested later for shortlisted applicants.